Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18896954 | 3D PRINTED BONE DEFECT REPAIR SCAFFOLD LOADED WITH EXTRACELLULAR MATRIX OF MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOF | September 2024 | May 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18841788 | DOUBLE-CROSSLINKED FIBRIN GEL, RAW MATERIAL COMPOSITION AND KIT THEREOF, AND APPLICATION THEREOF | August 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18624746 | BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODS | April 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18606551 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGS | March 2024 | August 2024 | Allow | 5 | 0 | 1 | No | No |
| 18542059 | BONE REGENERATION MATERIAL HAVING A COTTON-WOOL LIKE STRUCTURE FORMED OF A PLURALITY OF ELECTROSPUN FIBERS | December 2023 | February 2025 | Abandon | 14 | 1 | 1 | No | No |
| 18527884 | USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERS | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18448259 | BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODS | August 2023 | April 2024 | Allow | 8 | 1 | 1 | No | No |
| 18349570 | EPHEDRINE LIQUID FORMULATIONS | July 2023 | May 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18259697 | TRANSDERMAL PSYCHOACTIVE ALKALOID COMPOSITION AND PREPARATION THEREOF | June 2023 | April 2024 | Allow | 9 | 1 | 1 | No | No |
| 18312445 | SYSTEMS AND METHODS FOR BONE REPAIR AND MANAGEMENT USING BIOCOMPATIBLE POLYMERIC RESIN | May 2023 | September 2024 | Abandon | 16 | 1 | 1 | No | No |
| 18302975 | CONTROLLING NEUROPATHIC PAIN | April 2023 | September 2024 | Allow | 17 | 1 | 0 | No | No |
| 18093931 | Oral Drug Delivery System and Method for Fabricating Thereof | January 2023 | March 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18070334 | Microcapillary Mesh Oxygen Transporter for Cell Transplantations | November 2022 | June 2025 | Allow | 41 | 0 | 1 | No | No |
| 18070319 | Methods and compositions for treatment with donepezil | November 2022 | October 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17984291 | MEDICAL ADHESIVE AND PREPARATION METHOD THEREOF | November 2022 | October 2024 | Allow | 23 | 0 | 1 | No | No |
| 17981383 | FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF | November 2022 | August 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17969282 | Packaged Silicone Lubricated Condom That Provides Sensation | October 2022 | June 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17945575 | ELECTROSPINNING OF CARTILAGE AND MENISCUS MATRIX POLYMERS | September 2022 | March 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17932621 | SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES | September 2022 | December 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17902303 | MICRONEEDLE DEVICE | September 2022 | February 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17819346 | Structural Implant to Prevent Bone Defects | August 2022 | March 2025 | Allow | 31 | 2 | 1 | No | No |
| 17813517 | ABUSE RESISTANT CAPSULE | July 2022 | July 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17848418 | METHODS OF TREATMENT USING NICLOSAMIDE | June 2022 | September 2024 | Abandon | 26 | 2 | 1 | Yes | No |
| 17838810 | TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINE | June 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17834561 | DRY INFLATED DECELLULARIZED EXTRACELLULAR MATRIX | June 2022 | September 2024 | Allow | 28 | 2 | 1 | No | No |
| 17829627 | PINOCEMBRIN DIHYDROCHALCONE AND COMPOSITIONS THEREOF AND THEIR USE AS PESTICIDES | June 2022 | April 2025 | Allow | 34 | 0 | 1 | No | No |
| 17731348 | METHODS AND COMPOSITION FOR INDUCTION OF IMMUNE RESPONSE | April 2022 | December 2024 | Allow | 32 | 0 | 0 | No | No |
| 17722936 | Method of Controlling Insects and Insecticide for Use Therein | April 2022 | November 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17712755 | MICRONEEDLE PARTICLES, COMPOSITIONS, AND METHODS OF TREATMENT AND DELIVERING A SUBSTANCE OF INTEREST | April 2022 | April 2024 | Allow | 24 | 1 | 1 | No | No |
| 17696752 | WATER-SOLUBLE FORMULATIONS, METHODS OF MAKING AND USE | March 2022 | April 2023 | Abandon | 13 | 1 | 1 | No | No |
| 17654963 | BOUNDARY SURFACE CHARGED CONTACT LENS FOR DELIVERY | March 2022 | August 2022 | Allow | 5 | 0 | 1 | No | No |
| 17692460 | POROUS TRICALCIUM PHOSPHATE MATERIAL, METHOD FOR BONE HEALING USING THE SAME, AND MANUFACTURING METHOD THEREOF | March 2022 | June 2024 | Allow | 28 | 1 | 1 | No | No |
| 17588659 | MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIA | January 2022 | July 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17570216 | TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF | January 2022 | December 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17545931 | METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION | December 2021 | May 2024 | Allow | 29 | 1 | 1 | No | No |
| 17542432 | EPHEDRINE LIQUID FORMULATIONS | December 2021 | August 2023 | Abandon | 20 | 2 | 1 | No | No |
| 17529402 | USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERS | November 2021 | January 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17454846 | METHOD FOR PREPARING CERAMIC MATERIALS | November 2021 | January 2024 | Allow | 26 | 0 | 1 | No | No |
| 17519336 | POROUS COMPOSITE BIOMATERIALS AND RELATED METHODS | November 2021 | March 2024 | Allow | 29 | 3 | 1 | Yes | Yes |
| 17513307 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | October 2021 | May 2022 | Allow | 6 | 0 | 1 | Yes | No |
| 17603448 | TISSUE DERIVED POROUS MATRICES AND METHODS FOR MAKING AND USING SAME | October 2021 | April 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17485766 | BIOACTIVE POROUS BONE GRAFT IMPLANTS | September 2021 | May 2024 | Allow | 31 | 1 | 1 | No | No |
| 17437173 | PHOTOTHERMAL THERAPY PROMOTES TUMOR INFILTRATION AND ANTITUMOR ACTIVITY OF CART T CELLS | September 2021 | March 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17466142 | COMPOSITIONS FOR PREVENTING INFECTION | September 2021 | March 2025 | Allow | 42 | 5 | 1 | Yes | Yes |
| 17402172 | Medical Device Comprising Boswellic Acid | August 2021 | May 2024 | Allow | 33 | 1 | 1 | No | No |
| 17362203 | MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIA | June 2021 | September 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17416930 | PERCUTANEOUS ABSORPTION PREPARATION COMPRISING STABILIZED DONEPEZIL | June 2021 | August 2024 | Allow | 38 | 0 | 1 | No | No |
| 17304347 | BIODEGRADABLE ARTICLES AND METHODS FOR TREATMENT OF PELVIC FLOOR DISORDERS INCLUDING EXTRACELLULAR MATRIX MATERIAL | June 2021 | November 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17342807 | Disintegrating Oral Tablet Suitable For Active Pharmaceutical Ingredients | June 2021 | July 2024 | Allow | 37 | 2 | 1 | No | No |
| 17341785 | Oral Tablet For Taste Masking Of Active Ingredients | June 2021 | July 2024 | Allow | 37 | 2 | 1 | No | No |
| 17317540 | COMPOSITIONS AND METHODS FOR TREATMENT OF BONE DEFECTS | May 2021 | May 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17182767 | WATER-SOLUBLE FORMULATIONS, METHODS OF MAKING AND USE | February 2021 | September 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17180935 | POROUS COMPOSITE BIOMATERIALS AND RELATED METHODS | February 2021 | December 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17163113 | BIORESORBABLE IMPLANT WITH INSIDE-OUT RESORPTION FOR ENHANCED BONE INGROWTH AND TISSUE INTEGRATION AND METHOD OF MANUFACTURING THEREOF | January 2021 | January 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17262987 | BIOMIMETIC BIOMATERIAL AND PRODUCTION METHOD THEREOF | January 2021 | September 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17108689 | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF CANNABINOIDS AND TERPENOIDS | December 2020 | March 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17059206 | METHOD FOR MANUFACTURING RING-SHAPED BONE GRAFTING SUBSTITUTE | November 2020 | March 2025 | Allow | 52 | 2 | 2 | No | No |
| 17073312 | MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIA | October 2020 | April 2021 | Allow | 6 | 0 | 1 | Yes | No |
| 17064475 | BONE REGENERATION MATERIAL HAVING A COTTON-WOOL LIKE STRUCTURE FORMED OF A PLURALITY OF ELECTROSPUN FIBERS | October 2020 | August 2023 | Abandon | 35 | 6 | 0 | Yes | No |
| 17032905 | CURABLE CALCIUM PHOSPHATE COMPOSITIONS FOR USE WITH POROUS STRUCTURES AND METHODS OF USING THE SAME | September 2020 | December 2023 | Abandon | 39 | 2 | 1 | No | No |
| 17040999 | Preparation method of gradient mineralized cancellous bone matrix material | September 2020 | February 2023 | Allow | 29 | 0 | 0 | No | No |
| 17018491 | DEMINERALIZED BONE MATRIX FIBERS, METHODS OF MAKING AND USING THEM | September 2020 | April 2024 | Allow | 43 | 2 | 1 | No | No |
| 17018708 | HYDRATABLE COMPOSITIONS COMPRISING MACROPARTICLES AND METHODS OF MAKING THEM | September 2020 | April 2024 | Allow | 43 | 2 | 1 | No | No |
| 17006012 | ROLLABLE BONE IMPLANT FOR ENCLOSING BONE MATERIAL | August 2020 | December 2024 | Allow | 52 | 6 | 1 | No | No |
| 16986524 | ARTICLES INCLUDING BRUSHITE FOR USE AS A BONE OR DENTAL IMPLANT AND METHODS OF FORMING | August 2020 | October 2024 | Abandon | 50 | 2 | 1 | Yes | No |
| 16922422 | TREATED OSSEOUS PARTICULATE FLUFF COMPOSITION | July 2020 | January 2025 | Abandon | 54 | 6 | 1 | Yes | Yes |
| 16906967 | TISSUE PATCH | June 2020 | July 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16904590 | METHODS OF TREATMENT USING NICLOSAMIDE | June 2020 | October 2022 | Abandon | 28 | 4 | 1 | Yes | No |
| 16903008 | ZINC COMPOSITIONS FOR COATED MICRONEEDLE ARRAYS | June 2020 | January 2023 | Abandon | 31 | 2 | 1 | Yes | No |
| 16769698 | MEDICAL MATERIALS AND DEVICES | June 2020 | July 2024 | Abandon | 50 | 4 | 1 | No | No |
| 16886390 | METHOD FOR PRODUCING TABLET | May 2020 | October 2023 | Abandon | 41 | 3 | 1 | No | No |
| 16767579 | COMPOSITION OF A CALCIUM PHOSPHATE AND AN ADDITIVE COMPOUND CONTAINING A PHOSPHATE OR PHOSPHONATE GROUP | May 2020 | November 2023 | Allow | 41 | 2 | 1 | No | No |
| 16765790 | POUCH-TYPE ORALLY DISSOLVING FILMS WITH HIGH ACTIVE INGREDIENT CONCENTRATION | May 2020 | November 2024 | Abandon | 54 | 4 | 1 | Yes | No |
| 16867434 | METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION | May 2020 | October 2021 | Allow | 18 | 0 | 0 | No | No |
| 16864894 | DISSOLVABLE POLYMERIC EYE INSERTS AND METHOD OF USING SAME | May 2020 | June 2024 | Allow | 49 | 2 | 1 | Yes | Yes |
| 16759794 | TRANSDERMALLY ADMINISTRABLE PREPARATION | April 2020 | October 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16755219 | SOFT TISSUE REPAIR IMPLANTS COMPRISING HYDROXYBUTYRATE | April 2020 | March 2025 | Allow | 59 | 5 | 1 | Yes | No |
| 16754434 | DEVICE FOR THE NON-INVASIVE INDUCTION OF DYNAMIC DEFORMATION OF BODY TISSUE TO DIFFERENTIATE TISSUE CELLS | April 2020 | March 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 16834640 | COATED PARTICLES | March 2020 | December 2023 | Abandon | 45 | 3 | 1 | No | No |
| 16826485 | MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIA | March 2020 | July 2020 | Allow | 4 | 0 | 0 | No | No |
| 16648982 | MICROARCHITECTURE OF OSTEOCONDUCTIVE BONE SUBSTITUTE | March 2020 | April 2023 | Abandon | 37 | 1 | 1 | Yes | No |
| 16820219 | Platelet-Derived Growth Factor Formulations for Enhancing Spine Fusion | March 2020 | August 2024 | Abandon | 53 | 4 | 1 | No | No |
| 16810436 | Method of Controlling Insects and Insecticide for Use Therein | March 2020 | May 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16801128 | TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF | February 2020 | April 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16783256 | EXPANDABLE BONE AND TISSUE REGENERATION SYSTEM, AND APPLICATIONS OF SAME | February 2020 | September 2024 | Allow | 55 | 5 | 1 | No | No |
| 16778794 | Oral Drug Delivery System and Method for Fabricating Thereof | January 2020 | April 2023 | Abandon | 39 | 3 | 1 | No | No |
| 16633339 | PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB | January 2020 | August 2022 | Allow | 31 | 4 | 0 | Yes | No |
| 16631529 | COMPOSITIONS AND METHODS OF LIPOPHILIC DRUGS | January 2020 | April 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16716039 | PHARMACEUTICAL OR NUTRACEUTICAL SELF-EMULSIFYING SOLID DISPERSION COMPOSITION | December 2019 | April 2023 | Abandon | 40 | 3 | 1 | Yes | No |
| 16701616 | FORMULATION COMPRISING GLYCOPYRROLATE, METHOD AND APPARATUS | December 2019 | April 2023 | Abandon | 40 | 4 | 0 | No | No |
| 16699319 | WATER-SOLUBLE FORMULATIONS, METHODS OF MAKING AND USE | November 2019 | April 2023 | Abandon | 41 | 3 | 1 | No | No |
| 16615199 | TRANSDERMAL PATCH PACKAGING FILM | November 2019 | July 2023 | Allow | 44 | 4 | 1 | No | No |
| 16598189 | BONDED POWDERS FOR THE TREATMENT OF BODILY LESIONS | October 2019 | September 2021 | Abandon | 24 | 2 | 1 | Yes | No |
| 16603729 | TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINE | October 2019 | September 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16594039 | METHOD AND DEVICES FOR CELLULAR TRANSFER OF COMPOUNDS WITH AUGMENTED REALITY APPLICATION | October 2019 | December 2022 | Abandon | 38 | 4 | 1 | No | No |
| 16574699 | ABUSE DETERRENT IMMEDIATE RELEASE CAPSULE DOSAGE FORMS | September 2019 | June 2022 | Allow | 33 | 4 | 1 | No | No |
| 16494900 | METHODS AND MATERIALS FOR TREATING FISTULAS | September 2019 | January 2023 | Abandon | 40 | 2 | 1 | Yes | Yes |
| 16572148 | ABUSE RESISTANT CAPSULE | September 2019 | May 2022 | Allow | 32 | 3 | 1 | Yes | No |
| 16571402 | ANTIFUNGAL COMPOSITIONS AND METHODS OF USE THEREOF | September 2019 | May 2021 | Abandon | 20 | 2 | 0 | No | No |
| 16564587 | Composition for Patch Preparation Comprising Drug, Organic Solvent, Lipophilic Mass Base, and Powder | September 2019 | February 2024 | Allow | 53 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COUGHLIN, DANIEL F.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COUGHLIN, DANIEL F works in Art Unit 1619 and has examined 551 patent applications in our dataset. With an allowance rate of 41.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner COUGHLIN, DANIEL F's allowance rate of 41.9% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by COUGHLIN, DANIEL F receive 2.65 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by COUGHLIN, DANIEL F is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.4% benefit to allowance rate for applications examined by COUGHLIN, DANIEL F. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 11.8% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.1% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 81.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 62% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 67.2% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 48.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 69.6% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.4% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.